Scheduled a pre-IND meeting with the FDA, indicating progress in the regulatory pathway for EL-22. EL-22's novel approach targets muscle preservation for patients undergoing weight loss treatments, ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ...
NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative ...
HOUSTON, Aug. 28, 2025 /PRNewswire/ -- Stramsen Biotech Inc. has successfully submitted a Pre-Investigational New Drug (Pre-IND) meeting request, accompanied by a comprehensive Pre-IND package, to the ...
The meeting provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+™ PHILADELPHIA and VANCOUVER, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BriaCell ...
SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug ...
Northstrive Biosciences announced that it has scheduled a pre-Investigational New Drug, IND, meeting with the U.S. Food and Drug Administration for Wednesday, April 23, 2025. Northstrive will have a ...
BERKELEY, Calif., Sept. 24, 2025 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results